Lexeo Therapeutics (LXEO)

• Market cap: $253M
• 1 day: 6.57%
• 5 days: -0.65%
• 1 month: -4.64%
• 3 months: -33.48%
• 6 months: -49.67%
• Year to date: -67.95%
• 1 year: -63.85%
• 5 years: -69.35%
• 10 years: -69.35%
• Sector: Healthcare
• Industry: Biotechnology

About: Lexeo Therapeutics Inc is a clinical-stage genetic medicine company engaged in the development of gene therapy candidates targeting the underlying genetic causes of cardiovascular diseases. The company is advancing a portfolio of programs focused on conditions such as Friedreich ataxia, cardiomyopathy, plakophilin-2, or PKP2, and arrhythmogenic cardiomyopathy, with its lead candidates including LX2006 and LX2020. Its therapies utilize AAV-based vectors designed to deliver functional genes to cardiac cells to restore normal function and address high unmet medical needs.

Employees: 59